Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases in the United States. Its portfolio includes Qelbree, a non-stimulant for attention-deficit hyperactivity disorder (ADHD); GOCOVRI for dyskinesia in Parkinson's disease (PD); Oxtellar XR for partial onset epilepsy seizures; APOKYN for hypomobility or off episodes in advanced PD; Trokendi XR for epilepsy and migraine prophylaxis; XADAGO for off episodes in PD; and MYOBLOC for cervical dystonia and chronic sialorrhea. The company also has pipeline candidates: ONAPGO (FDA approved) for motor fluctuations in advanced PD, SPN-817 (Phase 2) for epilepsy and related syndromes, SPN-820 (Phase 2) for resistant depression, and SPN-443 (Phase 1) for ADHD/CNS.

Supernus Pharmaceuticals is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol SUPN. Its shares are traded in US dollars (USD), reflecting its primary listing in the United States. The company is headquartered in the United States and operates within the US market, focusing on the development and commercialization of CNS treatments.

Supernus Pharmaceuticals operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This means the company is involved in the research, development, and production of pharmaceutical products, with a focus on specialty drugs that treat specific conditions, as well as generic medications. In Supernus's case, its portfolio centers on central nervous system (CNS) disorders, including ADHD, epilepsy, Parkinson's disease, and depression, offering both branded and specialty treatments.

Supernus Pharmaceuticals has a diverse portfolio of CNS treatments. Key products include Qelbree (a non-stimulant for ADHD), GOCOVRI (for dyskinesia in Parkinson's disease), Oxtellar XR (extended-release oxcarbazepine for partial onset epilepsy), APOKYN (for acute off episodes in advanced Parkinson's), Trokendi XR (extended-release topiramate for epilepsy and migraine prophylaxis), XADAGO (for off episodes in Parkinson's), and MYOBLOC (a Type B toxin for cervical dystonia and chronic sialorrhea). Additionally, ONAPGO has received FDA approval for motor fluctuations in advanced Parkinson's. The pipeline includes SPN-817 (Phase 2 for epilepsy), SPN-820 (Phase 2 for resistant depression), and SPN-443 (Phase 1 for ADHD/CNS).

Supernus Pharmaceuticals generates revenue by developing and commercializing proprietary pharmaceutical products for central nervous system (CNS) diseases. The company focuses on both approved products and a pipeline of candidates in clinical trials. Its commercial portfolio includes several marketed drugs for ADHD, epilepsy, Parkinson's disease, and other CNS conditions, which are sold primarily in the United States. The company also invests in research and development to advance new therapies, such as SPN-817, SPN-820, and SPN-443, which target epilepsy, depression, and ADHD/CNS, respectively. By bringing these treatments to market, Supernus aims to address unmet medical needs in neurology and psychiatry.